Latest Cancer immunoprevention Stories
A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells. In a study conducted at Texas Biomed's Southwest National Primate Research Center, researchers found that the immune modulator GS-9620, which targets a receptor on immune cells, reduced both the virus levels and the number of infected liver cells in...
DES PLAINES, Ill., Nov. 28, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. (GSK) to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program. Companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more or less likely to benefit from a particular...
GOTHENBURG, Sweden, November 25, 2011 /PRNewswire/ -- Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial. - It's a big and important step to test the vaccine on humans for the first time. Our...
ROCKVILLE, Md., June 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11). ENMD-2076, EntreMed's lead oncology...
NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented in an oral presentation(1) at the 51st Annual Meeting of the American Society of Hematology (ASH) and were...
Older cancer sufferers need treatments tailored to their aging immune systemsElderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease. The challenge is to boost their immune response to cancer vaccines, because like the rest of our organs, our immune system ages and gradually becomes less efficient as we get older. Dr. Joseph Lustgarten, from the Mayo Clinic College of Medicine in the US, reviews the effects of aging on...
Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research."There are extremely precise mechanistic methods augmenting the ability of the immune system to distinguish between normal tissues and tumors," said lead researcher Richard G. Vile, Ph.D. "Understanding the multiple checks and safeguards against...
Hepatitis B virus (HBV) infection is a dynamic process with variable biochemical, virological and histological profiles at different stages of the infection, depending on host and viral factors. Furthermore, this profile may change at a variable pace over time. The correlation between detection of T-cell response and HBV load in chronic HBV infection remains unknown. In each of the clinical stages of chronic HBV infection, whether the composition of T-cell subpopulations is different and...
OSLO, Norway, April 28 /PRNewswire/ -- Affitech AS, the human antibody therapeutics company, announced today that preclinical data on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner Peregrine Pharmaceuticals at the 100th Annual Meeting of the American Association for Cancer Research (AACR) 2009 held during April 18 - 22, 2009 in Denver, CO. The preclinical studies of PGN635 and PGN632 provided further confirmatory evidence that the...
- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the Immune System - - Studies Confirm Peregrine's PS-Targeting Antibodies Stimulate Dendritic Cell Maturation, Inflammatory Cytokine and Chemokine Release and Recruitment of Macrophages to Tumors - DENVER and TUSTIN, Calif., April 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc....
